PDIGREE: An adaptive phase 3 trial of PD-inhibitor nivolumab and ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated renal cell cancer (Alliance A031704).
Year: 2019
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: Duke Medical Center, Weill Cornell Medicine, Dana-Farber Cancer Institute, University of North Carolina at Chapel Hill, University of Chicago, Mayo Clinic, University of Wisconsin–Madison, University of Minnesota, Masonic Cancer Center, Memorial Sloan Kettering Cancer Center, Duke Cancer Institute, Brigham and Women's Hospital, Harvard University, Dana-Farber Brigham Cancer Center
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4229551959